News

Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM
ALNY gains approval to expand Amvuttra's label in the EU, boosting its position as the only RNAi therapy for ATTR-CM.
PMLive9h
Alnylam’s Amvuttra granted EC approval to treat for rare heart disease ATTR-CM
Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been approved by the European Commission (EC) to treat adults with ...
EC approves Alnylam’s vutrisiran for ATTR-CM treatment
Amvuttra is the first and only RNA interference (RNAi) therapeutic approved by the EC for both the cardiomyopathy and the ...